个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wang Feng-Hua[1] * ; Zhang Xiao-Tian[2] * ; Tang Lei[3] ; Wu Qi[4] ; Cai Mu-Yan[5] ; Li Yuan-Fang[6] ; Qu Xiu-Juan[7] ; Qiu Hong[8] ; Zhang Yu-Jing[9] ; Ying Jie-Er[10] ; Zhang Jun[11] ; Sun Ling-Yu[12] ; Lin Rong-Bo[13] ; Wang Chang[14] ; Liu Hao[15] ; Qiu Miao-Zhen[1] ; Guan Wen-Long[1] ; Rao Sheng-Xiang[16] ; Ji Jia-Fu[17] ; Xin Yan[18] ; Sheng Wei-Qi[19] ; Xu Hui-Mian[20] ; Zhou Zhi-Wei[21] ; Zhou Ai-Ping[22] ; Jin Jing[23] ; Yuan Xiang-Lin[24] ; Bi Feng[25] ; Liu Tian-Shu[26] ; Liang Han[27] ; Zhang Yan-Qiao[28] ; Li Guo-Xin[15] ; Liang Jun[29] ; Liu Bao-Rui[30] ; Shen Lin[31,*3] ; Li Jin[32,*2] ; Xu Rui-Hua[1,*1] ;
机构： [1]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China. [2]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, P. R. China. [3]Department of Radiology, Peking University Cancer Hospital, Beijing, P. R. China. [4]Department of Endoscopy Center, Peking University Cancer Hospital, Beijing, P. R. China. [5]Department of Pathology, Sun Yat-sen University Cancer Center ,State Key Laboratory of Oncology in South China ,Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, P. R. China. [6]Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China. [7]Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China. [8]Department of Medical Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China. [9]Department of Radiotherapy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China. [10]Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China. [11]Department of Medical Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P. R. China. [12]Department of Surgical Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P. R. China. [13]Department of Medical Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, P. R. China. [14]Tumor Center, The First Hospital of Jilin University, Changchun, Jilin, P. R. China. [15]Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China. [16]Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China. [17]Department of Gastrointestinal Surgery, Peking University Cancer Hospital, Beijing, P. R. China. [18]Pathology Laboratory of Gastrointestinal Tumor, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China. [19]Department of Pathology, Zhongshan Hospital Affiliated to Shanghai Fudan University, Shanghai, P. R. China. [20]Department of Gastrointestinal Oncology Surgery. The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China. [21]Department of Gastric Surgery, Sun Yat-sen University Cancer Center ,State Key Laboratory of Oncology in South China ,Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, P. R. China. [22]Department of Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China. [23]Department of Radiation Oncology, Shenzhen hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, P. R. China. [24]Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China. [25]Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China. [26]Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, P. R. China. [27]Department of Gastric Surgery, Tianjin Medical University Cancer Institute &amp ,Hospital, Tianjin, P. R. China. [28]Department of Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, P. R. China. [29]Department of Medical Oncology, Peking University International Hospital, Beijing, P. R. China. [30]Department of Medical Oncology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, P. R. China. [31]Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, P. R. China. [32]Department of Oncology, Easter Hospital affiliated to Shanghai Tongji University, Shanghai, P. R. China.
出处：
DOI： 10.1002/cac2.12516
ISSN：

关键词： Chinese Society of Clinical Oncology (CSCO) gastric cancer diagnosis surgery neoadjuvant adjuvant radiotherapy chemotherapy targeted therapy immunotherapy

摘要：
The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in evidence-based medicine, healthcare resource availability, and precision medicine. These updates address the differences in epidemiological characteristics, clinicopathological features, tumor biology, treatment patterns, and drug selections between Eastern and Western gastric cancer patients. Key revisions include a structured template for imaging diagnosis reports, updated standards for molecular marker testing in pathological diagnosis, and an elevated recommendation for neoadjuvant chemotherapy in stage III gastric cancer. For advanced metastatic gastric cancer, the guidelines introduce new recommendations for immunotherapy, anti-angiogenic therapy and targeted drugs, along with updated management strategies for human epidermal growth factor receptor 2 (HER2)-positive and deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) patients. Additionally, the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric cancer. The 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice, particularly in the heterogeneous healthcare landscape of China, while maintaining a commitment to scientific rigor, impartiality, and timely revisions.© 2023 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China. [31]Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, P. R. China. [32]Department of Oncology, Easter Hospital affiliated to Shanghai Tongji University, Shanghai, P. R. China. [*1]Department of Medical Oncology, Sun Yat-sen University Cancer Center ,State Key Laboratory of Oncology in South China ,Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, Guangdong, P. R. China. [*2]Department of Oncology, Easter Hospital affiliated to Shanghai Tongji University, Shanghai 200120, P. R. China. [*3]Department of GI Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital. Beijing 100142, P. R. China
推荐引用方式(GB/T 7714)：
Wang Feng-Hua,Zhang Xiao-Tian,Tang Lei,et al.The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023[J].CANCER COMMUNICATIONS.2023,127-172.doi:10.1002/cac2.12516.
APA：
Wang Feng-Hua,Zhang Xiao-Tian,Tang Lei,Wu Qi,Cai Mu-Yan...&Xu Rui-Hua.(2023).The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.CANCER COMMUNICATIONS,,
MLA：
Wang Feng-Hua,et al."The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023".CANCER COMMUNICATIONS .(2023):127-172

相关文献

[1]The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. [2]The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma [3]The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. [4]Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer [5]PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer [6]Primary tracheal adenoid cystic carcinoma: adjuvant treatment outcome [7]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [8]Consensus, debate, and prospective on pancreatic cancer treatments [9]Adjuvant radiotherapy, chemotherapy or surgery alone for high-risk histological node negative esophageal squamous cell carcinoma: Protocol for a multicenter prospective randomized controlled trial [10]Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号